trending Market Intelligence /marketintelligence/en/news-insights/trending/ycaxfhririio3g7ozksncg2 content esgSubNav
In This List

Aclaris prices $92.9M common stock offering

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Aclaris prices $92.9M common stock offering

Aclaris Therapeutics Inc. priced a public offering of 8,645,000 common shares at $10.75 each, hoping to raise $92.9 million in gross proceeds.

The Wayne, Pa.-based biopharmaceutical company expects to close the offering Oct. 22.

Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering with Cantor serving as lead manager and Guggenheim Securities as co-manager.

The underwriters have a 30-day option to buy up to an additional 1,296,750 shares at $10.75 apiece from the company.

Aclaris develops therapies for medical and aesthetic dermatology and immunology in the U.S.